Not all patients respond to every biologic, which is why correct phenotyping before prescription is so important. If a biologic does not produce adequate clinical benefit after 4–6 months of therapy (assessed at Pulmovista Clinics using spirometry, exacerbation rates, and quality-of-life tools), Dr. Dixit Kumar Thakur will review the diagnosis, re-evaluate biomarkers, and consider switching to an alternative biologic or adding further therapy. The absence of response to one biologic does not mean all biologics will fail — the phenotype assessment guides the switch decision.